Atazanavir

Generic name
Atazanavir
Brand name
ATC Code
J05AE08
Compare …

Atazanavir

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Treatment HIV infection
  • Oral
    • Capsule, hard
      • ≥ 6 years and 15 up to 35 kg
        • 200 mg/day in 1 dose Combined with ritonavir (100 mg/day in a single dose).
        • Directions for administration:

          Take with food.

      • ≥ 6 years and ≥ 35 kg
        • 300 mg/day in 1 dose combined with ritonavir (100 mg/day in a single dose).
        • Directions for administration:

          take with food.

    • Powder for oral use
      • ≥ 3 months and 5 up to 15 kg
        • 200 mg/day in 1 dose Combined with ritonavir (80 mg/day in a single dose).
        • Directions for administration:

          Take with food. l (e.g. apple sauce or yoghurt) or drink (e.g. milk, infant formula or water).
          For infants who are not yet ingesting solid food or cannot drink from a cup, mix with a little infant formula and administer with a syringe. 

      • ≥ 3 months and 15 up to 35 kg
        • 250 mg/day in 1 dose Combined with ritonavir (80 mg/day in a single dose).
        • Directions for administration:

          Take with food.

      • ≥ 3 months and ≥ 35 kg
        • 300 mg/day in 1 dose Combined with ritonavir (100 mg/day in a single dose).
        • Directions for administration:

          Take with food.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Prolonged PQ and QT interval (more common in children)

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications in children

  • Use in children younger than 3 months due to the risk of kernicterus

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Children are susceptible to cardiac conduction disorders. Asymptomatic prolongation of the PQ interval has been reported more frequently in children than in adults, and asymptomatic first- and second-degree AV block has also been reported.

Ineffective: in pre-treated children, no efficacy is to be expected with ≥4 'protease inhibitor'(PI) mutations. This may be the case even with less than 4 'protease inhibitor'(PI) mutations.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

DIRECT ACTING ANTIVIRALS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB01
J05AB12
J05AB06
J05AB16
J05AB04
J05AB11
J05AB14
Phosphonic acid derivatives
J05AD01
Protease inhibitors
J05AE10
J05AE07
J05AE02
J05AE04
J05AE03
J05AE01
Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF06
J05AF02
J05AF09
J05AF10
J05AF05
J05AF04
J05AF07
J05AF13
J05AF13
J05AF01
Non-nucleoside reverse transcriptase inhibitors
J05AG06
J05AG03
J05AG04
J05AG01
J05AG05
Neuraminidase inhibitors
J05AH02
J05AH01
Antivirals for treatment of HIV infections, combinations
J05AR02
J05AR20
J05AR13
J05AR25
J05AR18
J05AR19
J05AR03
J05AR09
J05AR10
Other antivirals
J05AX28
J05AX12
J05AX07
J05AX09
J05AX08
J05AX24
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS
J05AR02
J05AR20
J05AR13
J05AR25
J05AR18
J05AR19
J05AR03
J05AR09
J05AR10
Integrase inhibitors
J05AJ04
Antivirals for treatment of HCV infections
J05AP54
J05AP57
J05AP51
J05AP08
J05AP55

References

  1. Bristol-Meyers Squibb Pharma EEIG, SmPC Reyataz poeder voor oraal gebruik (EU/1/03/267/007) Rev 52. 18-02-2022, www.ema.europa.eu
  2. Bristol-Meyers Squibb Pharma EEIG, SmPC Reyataz capsule (EU/1/03/267/004) Rev 52.18-02-2022, www.ema.europa.eu
  3. Bamford, A., et al (PENTA Steering Committee) (2015), Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. , HIV Med, doi:10.1111/hiv.12217
  4. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children., Guideline for the use of Antiretroviral agents in pediatric HIV infection, www.aidsinfo.nig.gov/contentfiles/lvguidelines/pediatricguidelines.pdf, Geraadpleegd 12 sept 2016, O1-O140
  5. Bamford, A., et al (PENTA Steering Committee) (2015), Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life., HIV Med, doi:10.1111/hiv.12217

Changes

Therapeutic Drug Monitoring


Overdose